… by baseline EF of ≤30% or New York Heart Association functional class III or IV HF. In …
rivaroxaban with or without aspirin on MACE and bleeding in COMPASS patients with or without …

… In the COMPASS (Cardiovascular Outcomes for … coronary artery disease (CAD) or peripheral
artery disease (PAD), the combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin …

… stable coronary artery disease or peripheral artery disease, the combination of rivaroxaban
(2.5 mg twice daily) and aspirin … with stable atherosclerotic vascular disease, rivaroxaban 2.5 …

… experienced fewer cardiovascular events but more bleeding complications than those
who … in cardiovascular risk in each rivaroxaban group compared with aspirin monotherapy. …

… For patients enrolled in LTOLE, we also report treatments (non-antithrombotic and
antithrombotic) received in the interval between the final rivaroxaban/aspirin visit and LTOLE …

… (CVD) but increases the risk of major bleeding. The aim of this study was to estimate the …
harm of adding low-dose rivaroxaban to aspirin in patients with stable cardiovascular disease. …

… and PAD patients at risk of cardiovascular events with rivaroxaban plus aspirin DPI improves
health outcomes and seems overall to be cost-effective compared with aspirin ATP, and …

… stable” coronary artery disease or PAD remain at a substantially increased long-term risk of
cardiovascular events… termed to have “stable” coronary artery disease are now referred to as …

… of the combination of rivaroxaban and aspirin compared with aspirin on sites, timing,
severity, and management of bleeding in the COMPASS (Cardiovascular Outcomes for People …

… patients undergoing stenting with atrial fibrillation, aspirin was removed and the strategy of
rivaroxaban plus a thienopyridine alone without aspirin reduced bleeding by 41% relative to …